文献速递精神分裂症与精神病性障碍会诊联络精神医学

精神病是多系统障碍吗?首发精神病中枢神经、免疫、心血管代谢和内分泌改变的Meta综述

Is psychosis a multisystem disorder? A meta-review of central nervous system, immune, cardiometabolic, and endocrine alterations in first-episode psychosis and perspective on potential models.
PubMed 文献 · Mol Psychiatry · 2018-05-09

该系统综述再分析165项研究共13440例样本,发现首发精神病患者在中枢神经系统、免疫、心血管代谢和HPA轴均存在改变,非中枢系统效应量总体与中枢系统相当,免疫改变效应量显著大于脑结构和神经化学改变,但非中枢改变与中枢改变及症状的关联证据有限且不一致。

要点

  • 首发精神病患者存在免疫、心血管代谢和HPA轴等非中枢系统改变。
  • 非中枢系统总体效应量(g=0.58)与中枢系统(g=0.50)无显著差异。
  • 免疫改变效应量(g=1.19)显著大于脑结构(P<0.001)和神经化学改变(P<0.001)。

核心结论

  • 首发精神病患者存在稳健的非中枢系统改变,其效应量与中枢系统改变大致相当。
  • 非中枢系统改变与中枢改变及症状的关联证据有限且不一致。

研究设计与样本

  • 系统Meta综述,检索PubMed并采用AMSTAR评估纳入Meta分析的方法学质量。
  • 提取165项病例对照研究数据,总样本量13440例。
  • 重新进行随机效应Meta分析,计算各参数及系统层面汇总效应量,并用Rosenthal失安全数评估稳健性。

主要发现

  • 与健康对照相比,首发精神病患者免疫参数汇总效应量g=1.19,心血管代谢参数g=0.23,HPA参数g=0.68。
  • 脑结构汇总效应量g=0.40,神经生理g=0.80,神经化学g=0.43。
  • 非中枢系统总体汇总效应量g=0.58,中枢系统总体g=0.50,两者无显著差异。
  • 免疫改变效应量显著大于脑结构(P<0.001)和神经化学改变(P<0.001)。
  • 心血管代谢改变效应量显著低于神经化学(P=0.04)、神经生理(P<0.001)和脑结构改变(P=0.001);HPA改变与三者均无显著差异。

关键数值与推荐

  • 免疫参数汇总效应量g=1.19(首发精神病 vs 健康对照)。
  • 心血管代谢参数汇总效应量g=0.23(首发精神病 vs 健康对照)。
  • HPA参数汇总效应量g=0.68(首发精神病 vs 健康对照)。
  • 脑结构g=0.40、神经生理g=0.80、神经化学g=0.43(首发精神病 vs 健康对照)。
  • 非中枢系统总体g=0.58,中枢系统总体g=0.50,两者无显著差异。

临床怎么用

  • 临床评估首发精神病患者时应关注免疫、心血管代谢和HPA轴等非中枢系统异常。
  • 治疗中可考虑对非中枢系统改变进行早期监测和干预,以降低共病和超额死亡风险。

局限性

  • 非中枢系统改变与中枢改变及症状的关联证据有限且不一致。
  • 研究基于病例对照数据,无法推断因果关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

People with psychotic disorders show abnormalities in several organ systems in addition to the central nervous system (CNS); and this contributes to excess mortality. However, it is unclear how strong the evidence is for alterations in non-CNS systems at the onset of psychosis, how the alterations in non-CNS systems compare to those in the CNS, or how they relate to symptoms. Here, we consider these questions, and suggest potential models to account for findings. We conducted a systematic meta-review to summarize effect sizes for both CNS (focusing on brain structural, neurophysiological, and neurochemical parameters) and non-CNS dysfunction (focusing on immune, cardiometabolic, and hypothalamic-pituitary-adrenal (HPA) systems) in first-episode psychosis (FEP). Relevant meta-analyses were identified in a systematic search of Pubmed and the methodological quality of these was assessed using the AMSTAR checklist (A Measurement Tool to Assess Systematic Reviews). Case-control data were extracted from studies included in these meta-analyses. Random effects meta-analyses were re-run and effect size magnitudes for individual parameters were calculated, as were summary effect sizes for each CNS and non-CNS system. We also grouped studies to obtain overall effect sizes for non-CNS and CNS alterations. Robustness of data for non-CNS and CNS parameters was assessed using Rosenthal's fail-safe N. We next statistically compared summary effect size for overall CNSand overall non-CNS alterations, as well as for each organ system separately. We also examined how non-CNS alterations correlate CNS alterations, and with psychopathological symptoms. Case-control data were extracted for 165 studies comprising a total sample size of 13,440. For people with first episode psychosis compared with healthy controls, we observed alterations in immune parameters (summary effect size: g = 1.19), cardiometabolic parameters (g = 0.23); HPA parameters (g = 0.68); brain structure (g = 0.40); neurophysiology (g = 0.80); and neurochemistry (g = 0.43). Grouping non-CNS organ systems together provided an effect size for overall non-CNS alterations in patients compared with controls (g = 0.58), which was not significantly different from the overall CNS alterations effect size (g = 0.50). However, the summary effect size for immune alterations was significantly greater than that for brain structural (P < 0.001) and neurochemical alterations (P < 0.001), while the summary effect size for cardiometabolic alterations was significantly lower than neurochemical (P = 0.04), neurophysiological (P < 0.001), and brain structural alterations (P = 0.001). The summary effect size for HPA alterations was not significantly different from brain structural (P = 0.14), neurophysiological (P = 0.54), or neurochemical alterations (P = 0.22). These outcomes remained similar in antipsychotic naive sensitivity analyses. We found some, but limited and inconsistent, evidence that non-CNS alterations were associated with CNS changes and symptoms in first episode psychosis. Our findings indicate that there are robust alterations in non-CNS systems in psychosis, and that these are broadly similar in magnitude to a range of CNS alterations. We consider models that could account for these findings and discuss implications for future research and treatment.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Pillinger T, D'Ambrosio E, McCutcheon R, et al. Is psychosis a multisystem disorder? A meta-review of central nervous system, immune, cardiometabolic, and endocrine alterations in first-episode psychosis and perspective on potential models. Mol Psychiatry. 2018. PMID: 29743584. doi:10.1038/s41380-018-0058-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。